ATE412746T1 - Verfahren zur hemmung der wirkung der osteoklasten - Google Patents

Verfahren zur hemmung der wirkung der osteoklasten

Info

Publication number
ATE412746T1
ATE412746T1 AT99923021T AT99923021T ATE412746T1 AT E412746 T1 ATE412746 T1 AT E412746T1 AT 99923021 T AT99923021 T AT 99923021T AT 99923021 T AT99923021 T AT 99923021T AT E412746 T1 ATE412746 T1 AT E412746T1
Authority
AT
Austria
Prior art keywords
receptors
osteoclasts
inhibiting
effect
isolated
Prior art date
Application number
AT99923021T
Other languages
English (en)
Inventor
Dirk Anderson
Laurent Galibert
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE412746T1 publication Critical patent/ATE412746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99923021T 1998-05-14 1999-05-13 Verfahren zur hemmung der wirkung der osteoklasten ATE412746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8548798P 1998-05-14 1998-05-14
US11083698P 1998-12-03 1998-12-03

Publications (1)

Publication Number Publication Date
ATE412746T1 true ATE412746T1 (de) 2008-11-15

Family

ID=26772773

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99923021T ATE412746T1 (de) 1998-05-14 1999-05-13 Verfahren zur hemmung der wirkung der osteoklasten
AT08015570T ATE517916T1 (de) 1998-05-14 1999-05-13 Verfahren zur hemmung der wirkung der osteoklasten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08015570T ATE517916T1 (de) 1998-05-14 1999-05-13 Verfahren zur hemmung der wirkung der osteoklasten

Country Status (12)

Country Link
US (2) US20050089522A1 (de)
EP (2) EP1076699B1 (de)
JP (1) JP2002514418A (de)
AT (2) ATE412746T1 (de)
AU (1) AU762574B2 (de)
CA (1) CA2328140C (de)
CY (1) CY1111912T1 (de)
DE (1) DE69939822D1 (de)
DK (1) DK2009025T3 (de)
ES (1) ES2317694T3 (de)
PT (1) PT2009025E (de)
WO (1) WO1999058674A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1998025958A2 (en) * 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
EP2003203A1 (de) 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
EP2336168A1 (de) 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002064782A2 (en) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
EA200301041A1 (ru) * 2001-03-22 2004-08-26 Барнс-Джуиш Хоспитал Стимуляция остеогенеза с использованием гибридных белков лиганда для rank
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
EP1399175A4 (de) * 2001-05-17 2005-11-30 Immunex Corp Therapeutische verwendung von rang-antagonisten
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
EP1442297A4 (de) * 2001-10-12 2004-12-15 Barnes Jewish Hospital Verfahren zur durchmusterung von osteogenen verbindungen
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
JP5191487B2 (ja) * 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
WO1994010308A1 (en) * 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP0822984A4 (de) 1995-04-27 2000-05-03 Human Genome Sciences Inc Rezeptor für humanen tumor nekrosis faktor
AU693713B2 (en) * 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
WO1998025958A2 (en) 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
WO1998028423A2 (en) 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP2003203A1 (de) * 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2336168A1 (de) * 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Also Published As

Publication number Publication date
WO1999058674A3 (en) 2000-02-10
CA2328140C (en) 2012-03-13
AU3988899A (en) 1999-11-29
CY1111912T1 (el) 2015-11-04
DE69939822D1 (de) 2008-12-11
US20090004196A1 (en) 2009-01-01
US20050089522A1 (en) 2005-04-28
WO1999058674A2 (en) 1999-11-18
PT2009025E (pt) 2011-09-19
ATE517916T1 (de) 2011-08-15
US7790684B2 (en) 2010-09-07
EP1076699A2 (de) 2001-02-21
DK2009025T3 (da) 2011-11-14
AU762574B2 (en) 2003-06-26
EP2009025A1 (de) 2008-12-31
EP2009025B1 (de) 2011-07-27
JP2002514418A (ja) 2002-05-21
ES2317694T3 (es) 2009-04-16
CA2328140A1 (en) 1999-11-18
EP1076699B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE517916T1 (de) Verfahren zur hemmung der wirkung der osteoklasten
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
DE69527987D1 (de) Formulierungen und verfahren zur reduzierung von hautreizung
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
EP1432431A4 (de) Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21-rezeptors
EP1438054A4 (de) Verfahren und zusammensetzungen zur behandlung von flaviviren und pestiviren mit 4'-modifiziertem nucleosid
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE240107T1 (de) Neue verbesserte formulierung zur behandlung der osteoporose
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60217479D1 (de) Verfahren zur kontinuierlichen behandlung von wasser aus zahnärztlichen geräten
EE200100125A (et) TAN-1057 derivaadid
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties